Piramal Pharma targets mid-teen FY27 growth, favours organic expansion
Piramal Pharma is prioritising greenfield and organic investment over acquisitions after April–June revenue rose 17% year on year to Rs 2,270 crore. EBITDA increased 72% to Rs 285 crore, lifting margin by 400 basis points to 12.5%.
Piramal Pharma targets mid-teen FY27 revenue growth and faster EBITDA expansion, prioritising greenfield and organic investment over acquisitions. Its consumer healthcare, CDMO and hospital generics units posted mid- to high-teen growth, supported by capacity utilisation and demand.
Why this matters
The organic-expansion focus follows Piramal Pharma's recent Q1 loss narrowing, when consumer-health e-commerce rose 40%, and signals investment-led growth rather than dealmaking.
Retail-company signals are accelerating, up 311700% QoQ.